Observation Of Clinical Efficacy Of Midnight-noon Ebb-flow Low Frequency Therapy In The Prevention And Treatment Of Chemotherapy Induced Nausea And Vomiting In Breast Cancer

Objective:To observe the efficacy and safety of Midnight-noon ebb-flow low frequency therapy combined with Western medicine antiemetic triple therapy compared with Western medicine antiemetic triple therapy alone on nausea and vomiting induced by anthracycline and cyclophosphamide chemotherapy in breast cancer,for clinical prevention and treatment of Midnight-noon ebb-flow low frequency therapy Chemotherapy induced nausea and vomiting provide clinical data.Method:Using a prospective randomized controlled study design,using Doll’s clinical case randomization table method,68 patients with breast cancer who met the inclusion criteria with chemotherapy regimens containing anthracyclines and cyclophosphamide were randomized into the observation group or the control group,with 34 patients in each group.The observation group was treated with Midnight-noon ebb-flow low frequency therapy combined with Western medicine antiemetic triple therapy,that is,on the basis of the Western medicine antiemetic triple therapy of Dolasetron + Dexamethasone + Olanzapine,and at the same time received Midnight-noon ebb-flow low frequency therapy device in chemotherapy D1-D5.The control group was treated with simple western medicine antiemetic triple therapy.The general information and KPS score of the patients were recorded before chemotherapy.According to the NCI-CTCEA5.0 grading standard,the nausea and vomiting grades and adverse reactions of the subjects on D1-D5(0-120h)were recorded every 24 hours after the start of chemotherapy.The scores of the Nausea and Vomiting Living Function Index(FLIE)completed by the patients themselves were recorded on D2 and D6 after chemotherapy.Record the albumin value of the patient before and after treatment.Using SPSS26.0 software for statistical analysis.Result:1.General data comparison: A total of 68 subjects were included in this study,and 62 patients finally completed the treatment.There were no significant differences in general data between the two groups in terms of age,height,weight,body surface area,tumor stage,chemotherapy regimen,KPS score,whether it was postoperative chemotherapy,history of morning sickness,and history of motion sickness(P>0.05),the baseline balance of the two groups was comparable.2.Comparison of main outcomes:(1)Severity classification of nausea and vomiting: Both groups had different degrees of nausea and vomiting after chemotherapy,and there was no statistical significance in the classification of nausea and vomiting in the two groups on D1(0-24h)(P>0.05).The symptom grade of the observation group in the delayed period(25-120h)after intervention was lower than that of the control group(P<0.05).(2)Days of nausea and vomiting: There was no significant difference in the days of nausea between the two groups(P>0.05).The days of vomiting after intervention in the observation group were less than those in the control group(P<0.05).(3)Complete remission rate: There was no significant difference in the complete remission rate of nausea and vomiting between the two groups in the acute phase(0-24h)(P>0.05).The complete remission rate of nausea and vomiting in the observation group in the delayed period and the whole period after treatment is higher than that in the control group(P<0.05).(4)Effective rate: There was no significant difference in the effective rate of nausea and vomiting in the acute phase between the two groups(P>0.05).The effective rate of the experimental group on nausea and vomiting is higher than that of the control group in the delayed period and the whole period(P<0.05).3.Comparison of secondary outcomes:(1)Albumin: There was no significant difference in albumin between the two groups before treatment(P>0.05),compared with before treatment,the albumin in both groups decreased after treatment(P<0.05),but the decrease in the level of albumin in the observation group was smaller than that in the control group(P<0.05).(2)Nausea and Vomiting Life Function Index(FLIE): The FLIE scores of the experimental group in the acute and delayed phases were higher than those of the control group(P<0.05),It can be seen that the quality of life of the patients in the experimental group was better than that in the control group after the intervention.(3)Evaluation of safety and adverse reactions: the adverse reactions of the two groups of subjects were all grades 1-2,and there were no adverse reactions of grade 3 or above.The incidence of abdominal distension and constipation in the experimental group was lower than that in the control group,and the differences were as statistical significance(P<0.05).Conclusions:1.On the basis of western medicine triple therapy combined with Midnight-noon ebb-flow low frequency therapy,it can reduce the symptom grade of nausea and vomiting in the delayed phase of breast cancer patients after chemotherapy,and improve the complete remission rate and effective rate of nausea and vomiting in the delayed phase.2.On the basis of Western medicine triple therapy,Midnight-noon ebb-flow low frequency therapy can improve the complete remission rate and effective rate of nausea and vomiting in breast cancer patients after chemotherapy,and can reduce the number of days of vomiting.3.On the basis of the triple therapy of western medicine,Midnight-noon ebb-flow low frequency therapy can improve the patient’s life index,and improve the patient’s quality of life.4.Midnight-noon ebb-flow low frequency therapy has high safety.On the basis of the triple therapy of Western medicine,Midnight-noon ebb-flow low frequency therapy can reduce the incidence of abdominal distension and constipation.